This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
The outcome of the HELIOS-B study — expected at the end of June or early July — is an enormous stock-moving event for Alnylam Pharmaceuticals. Billions of dollars in potential revenue — sufficient to power Alnylam into profitability — are on the line.
The results will also impact competitors, including BridgeBio Pharma and Ionis Pharmaceuticals.
